Cardiology

Acute Coronary Syndrome

Also known as ACS · Myocardial infarction · MI · Heart attack · STEMI · NSTEMI · Unstable angina

Acute coronary syndrome (ACS) spans STEMI (ST elevation, complete coronary occlusion, emergency reperfusion), NSTEMI (troponin-positive, no ST elevation), and unstable angina (troponin-negative). Diagnosis rests on the early 12-lead ECG and high-sensitivity troponin. Immediate treatment: chewed aspirin + a P2Y12 inhibitor + a parenteral anticoagulant; STEMI needs primary PCI when transfer to a cath lab is achievable within two hours (DANAMI-2) or early fibrinolysis with bolus tenecteplase (STREAM); NSTE-ACS is risk-stratified — TIMACS sent the high-risk third of patients to angiography within 24 hours.

High yieldHigh evidenceUpdated 26 July 202626 min readVerification in progress

Practise this topic

Plate IFigure from this chapter
On this page
Study tools

Exam tags

NEET-PGINICETUSMLEPLAB

Red flags

  • ST elevation in ≥2 contiguous leads (or new LBBB with ischaemic symptoms) = STEMI — activate the cath lab, door-to-balloon under 90 minutes
  • Inferior STEMI with hypotension and clear lung fields = right ventricular infarction — avoid nitrates and diuretics, give fluids
  • Tearing chest pain radiating to the back with a pulse/BP differential between limbs = exclude aortic dissection BEFORE giving antiplatelets or anticoagulants
  • New pansystolic murmur days after MI = papillary muscle rupture or ventricular septal rupture — urgent echocardiogram and surgical referral
  • Isolated ST depression in V1–V3 with tall R waves = posterior STEMI-equivalent — record posterior leads V7–V9

Meet the patient

A 58-year-old smoker arrives at 3am with central chest pressure he calls "an elephant on my chest", radiating to both arms, sweaty, nauseous, breathless for the last hour. The ECG shows ST elevation in V2 to V4. The cath lab is already being called before his troponin comes back.[1]

The two questions that decide his next hour are the two that decide every ACS: is the artery occluded? (the ECG answers within ten minutes) and can I open it in time? (the clock answers over the next two hours). Hold those two questions and everything below slots into place.[1]

One spectrum, one trigger, three faces

ACS is not three diseases — it is one plaque rupture read through two tests. Every episode begins the same way: an atherosclerotic cap tears or erodes, exposing thrombogenic core to flowing blood, and a platelet-and-fibrin clot forms over it. What happens next depends only on how completely that clot chokes the lumen — and the ECG plus troponin tell you that within an hour.[1]

The Fourth Universal Definition of Myocardial Infarction (2018) is the document examiners quote, and it draws one line every candidate must reproduce: acute myocardial injury is a rise and/or fall of troponin with at least one value above the 99th-percentile upper reference limit (URL). That injury only becomes infarction when there is also clinical evidence of ischaemia — symptoms, new ECG changes, Q waves, imaging evidence of lost myocardium, or a coronary thrombus. Troponin up in sepsis with a flat ECG is injury, not infarction; treat the sepsis.[3]

Because the mechanism matters as much as the label, the Universal Definition sorts MI into five types — and a final-prof candidate is expected to reproduce them:[3]

Type 1 — spontaneous

  • Plaque rupture, erosion or dissection with intraluminal thrombus
  • The classic ACS — full reperfusion and DAPT pathway applies
  • Example: ruptured LAD plaque with anterior STEMI

Type 2 — supply-demand

  • Oxygen mismatch WITHOUT plaque rupture; fixed CAD plus a precipitant
  • Tachyarrhythmia, hypotension, hypoxaemia, severe anaemia, hypertensive crisis
  • Treat the precipitant — not a loading-DAPT-and-angiogram pathway

Type 3 — sudden death

  • MI causing death before biomarkers could be drawn
  • Ischaemic symptoms with new ECG changes or imaging
  • Example: cardiac arrest with ST elevation, death before troponin

Type 4 and 5 — procedural

  • 4a: related to PCI; 4b: stent thrombosis; 4c: restenosis
  • 5: related to CABG
  • Defined by troponin thresholds multiplied by the URL
[3]

The classic trap: a septic, tachycardic patient with known coronary disease and a troponin bump is the ward's commonest Type 2 MI. Reaching for loading DAPT and rushing to angiography is the recurring trainee error — the artery did not rupture, the demand outran the supply, and the fix is the precipitant.[3]

The ECG-and-troponin fork — three faces

Two tests, applied early, do almost all of the diagnostic work. The bedside split every decision hangs on:[1]

STEMI

  • Complete occlusion, transmural ischaemia
  • ST elevation in at least 2 contiguous leads, OR new LBBB with ischaemic symptoms
  • Troponin rises (transmural necrosis)
  • Emergency reperfusion — primary PCI or fibrinolysis

NSTEMI

  • Subtotal occlusion, subendocardial ischaemia
  • ST depression, T-wave inversion, or a normal ECG
  • Troponin rises above the 99th-percentile URL with a rise/fall
  • Risk-stratified (GRACE/TIMI) for invasive timing

Unstable angina

  • Ischaemic symptoms at rest, new-onset, or crescendo
  • ECG may show transient changes or be normal
  • Troponin stays normal — no myocyte necrosis
  • Shrinking category in the high-sensitivity troponin era
[1]

The mechanistic split is the teaching point that earns marks: STEMI is a plumbing emergency — the artery must be opened now, regardless of how the biomarkers eventually look — while NSTE-ACS is a risk-stratification problem, where angiography is timed from the clinical picture, the ECG, and a validated score.[1]

One examiner favourite: why is unstable angina disappearing? Because high-sensitivity troponin now catches the small rises that used to be missed, reclassifying them as NSTEMI. Unstable angina survives only for the truly troponin-negative ischaemic presentation.[3]

Read the ECG like the cath lab does

The STEMI thresholds are the single most reproduced numbers in cardiology exams. New ST elevation at the J-point, in two contiguous leads:[1]

  • At least 1 mm (0.1 mV) in every lead except V2–V3.
  • In V2–V3: at least 2 mm in men aged 40 or older, 2.5 mm in men under 40, and 1.5 mm in women (any age).
  • Contiguous means anatomically adjacent: II/III/aVF inferior, V1–V4 anterior or septal, I/aVL/V5–V6 lateral.
  • New LBBB with a compatible history is a STEMI-equivalent.
  • Posterior MI is a STEMI-equivalent: tall R waves with ST depression in V1–V2, confirmed by ST elevation in V7–V9.[1]

The classic trap: V1–V2 ST depression with tall R waves is not "ischaemia or NSTEMI" — it is a posterior STEMI-equivalent. Record V7–V9 and activate reperfusion; do not wait for the troponin. The ECG defines the emergency now; the troponin measures the infarct later.[1]

The earlier, subtler signs the cath lab looks for before the ST elevation is obvious:[1]

  • Hyperacute T waves — tall, broad-based T waves within minutes of occlusion; the earliest electrical sign, and easily missed.
  • de Winter T waves — upsloping ST depression in the anterior leads with tall symmetrical T waves and no STE; an LAD-occlusion equivalent.
  • Wellens syndrome — deeply inverted or biphasic T waves in V2–V3 in a pain-free patient with critical proximal LAD stenosis; a pending-anterior-MI warning.
  • Right ventricular infarction — ST elevation in V3R–V4R in the setting of inferior STEMI. Record right-sided leads in every inferior STEMI.
  • Sgarbossa criteria in LBBB or a paced rhythm — concordant ST elevation at least 1 mm in any lead, concordant ST depression at least 1 mm in V1–V3, or discordant ST elevation at least 5 mm (Smith-modified uses a proportional ST/S ratio of -0.25 or more negative). Any one is highly specific.[24]

A normal first ECG does not exclude ACS. Serial ECGs every 15–30 minutes and troponin are needed, above all for circumflex-territory ischaemia, which is notoriously ECG-silent because the LCx supplies the high posterior wall the standard 12 leads barely see.[1]

How common, who, and why the plaque ruptures

Ischaemic heart disease is the leading cause of death worldwide, and India's burden has shifted the same way — cardiovascular disease accounted for 28.1 percent of all deaths in India in 2016, nearly double the 15.2 percent of 1990, with 23.8 million prevalent cases of ischaemic heart disease. This is the transition the NEET-PG and INICET examiner expects you to know. Risk factors split cleanly into the ones you cannot change and the ones you can.[26][1]

The non-modifiable set: age (risk rises steeply after 55 in men, 65 in women), male sex until menopause narrows the gap, family history of premature coronary disease (a first-degree relative under 55 in men, under 65 in women), and the genetic dyslipidaemias such as familial hypercholesterolaemia.[1]

The modifiable set, in order of how much they contribute: smoking (the single largest population-attributable risk, and the one whose cessation most rapidly lowers it), hypertension, diabetes (which roughly doubles vascular risk — hazard ratio 2.00 for coronary heart disease across 102 prospective studies — and is treated as a coronary-risk equivalent), dyslipidaemia (raised LDL-C, low HDL-C), obesity, sedentary lifestyle, chronic kidney disease, and psychosocial stress.[1][27]

Not all risk factors accelerate atherosclerosis equally — some specifically thin the fibrous cap and prime it to rupture: smoking, hypertension, and hypercholesterolaemia. And when the patient does not fit the typical profile, name the non-atherosclerotic mimics: cocaine-induced spasm, spontaneous coronary artery dissection (SCAD) in peripartum women, coronary embolism from endocarditis or atrial fibrillation, coronary arteritis (Kawasaki, Takayasu), and paradoxical embolism through a patent foramen ovale.[1]

Time is muscle — the wavefront of necrosis

Atherosclerosis builds silently for decades — a fatty streak of lipid-laden macrophages (foam cells) appears even in adolescence, then matures into a fibrous plaque with a lipid-rich necrotic core under a cap of smooth muscle and collagen. ACS begins the moment that cap ruptures (the commonest mechanism, in inflamed thin-capped plaques) or erodes (more often in women, in plaques without a large lipid core), exposing core and tissue factor to flowing blood.[1]

FigurePlaque rupture exposes the lipid core and tissue factor; platelets adhere via glycoprotein Ib to von Willebrand factor, activate, and aggregate through glycoprotein IIb/IIIa around a fibrin mesh, forming the occlusive thrombus that defines the ACS event. (AI-generated educational illustration.)

The thrombus then builds along two parallel pathways — and each is the target of one limb of your immediate drug bundle:[1]

  • Platelets adhere to exposed von Willebrand factor and collagen through GP-Ib and GP-VI, activate, release ADP and thromboxane A2, and cross-link through GP-IIb/IIIa binding fibrinogen. This is why aspirin (cyclo-oxygenase, thromboxane A2 blockade) and the P2Y12 inhibitors (ADP-receptor blockade) are the twin pillars.
  • The coagulation cascade — tissue factor fires the extrinsic pathway, generating thrombin, which converts fibrinogen to fibrin and further activates platelets. This is the target of heparin, enoxaparin, and fondaparinux.[1]

How completely the thrombus chokes the lumen decides the syndrome. A totally occlusive clot cuts flow to the full wall thickness — transmural ischaemia, ST elevation, STEMI. A subtotal or mural clot leaves some flow, so the innermost subendocardium (the layer furthest from the epicardial supply, under the highest wall tension, last fed and first starved) ischaemia — ST depression or T inversion, NSTEMI if necrosis follows, unstable angina if it does not.[1]

The wavefront is the reason "time is muscle" is literal, not a slogan. Necrosis starts in the subendocardium and spreads toward the subepicardium the longer the artery stays shut. In the canine model that established this, transmural necrosis was 38 percent of the wall at risk after 40 minutes of occlusion, 57 percent after 3 hours and 71 percent after 6 hours — salvageable subepicardial muscle persists for at least 3 hours. Coronaries are functional end-arteries with minimal acute collateral supply, which is why one vessel occluding can be catastrophic, and why every minute of reperfusion delay costs viable myocardium.[20]

FigureThe wavefront of necrosis: cell death begins subendocardially and spreads transmurally over hours — 38 percent of the wall at risk at 40 minutes, 71 percent at 6 hours in the canine model, the mechanistic basis of 'time is muscle'. Coronary territories map predictably to ECG leads. (AI-generated educational figure.)

The territory table is core exam material — memorise the mapping, because the ECG tells you the culprit before anyone opens the chest:[1]

ECG localisation of STEMI to culprit coronary artery
ST-elevation leadsTerritoryCulprit arteryPearl
II, III, aVFInferiorRight coronary artery (RCA)Check V3R–V4R for RV infarct; reciprocal ST depression in I, aVL
V1–V4Anterior / anteroseptalLeft anterior descending (LAD)Largest infarcts, highest arrhythmia and shock risk
I, aVL, V5–V6LateralLeft circumflex (LCx)Often ECG-silent — a normal ECG does not exclude LCx occlusion
V7–V9 (posterior)PosteriorRCA or LCxPresents as tall R plus ST depression in V1–V2; a STEMI-equivalent
V3R–V4R (right)Right ventricleProximal RCANitrate-sensitive — give fluids, avoid diuretics
[1]

Etymology for viva gold: infarction is from Latin infarctus, past participle of infarcire, "to stuff" (in- plus farcire, to stuff) — the dead myocardium is, histologically, stuffed in among the living. Coronary comes from corona, "crown", because the arteries crown the heart. The Universal Definition keeps the word infarction for necrosis caused by ischaemia and reserves injury for a troponin rise above the 99th-percentile URL without it.[3]

Meet the atypical presentations — the ones that bite

Classic ACS pain is retrosternal pressure, tightness or heaviness, radiating to the left arm, both arms, neck, jaw, or epigastrium, lasting more than 20 minutes if infarction is evolving, with autonomic features — sweating, nausea, vomiting, dyspnoea, syncope. Effort pain becoming rest pain, crescendo angina, or new limiting angina all define the unstable patterns.[1]

It is the atypical presentations that hurt patients, because they are missed:[1]

  • Women, the elderly, and diabetics may have dyspnoea alone, fatigue, epigastric pain, nausea, confusion, or syncope — and no crushing pain.
  • Silent MI is discovered later on ECG (Q waves) or imaging; common in diabetes with autonomic neuropathy.
  • Inferior MI hides as epigastric pain with vagal features (bradycardia, nausea) and is sent home as gastritis.
  • Right ventricular infarction is inferior MI plus hypotension, clear lungs, and a raised JVP.
  • Posterior MI may show almost nothing on a standard 12-lead.[1]

Three worked stems to carry into the viva:[1]

  • A 70-year-old diabetic woman with sudden dyspnoea and no chest pain, anterior Q waves and a troponin rise — this is a silent anterior MI, not "CCF only". Work her up as ACS.
  • A 45-year-old with tearing pain to the back and unequal arm blood pressures — this is dissection until proven otherwise, not MONA first. An anticoagulated dissection can be fatal.
  • Post-prandial epigastric burning in a sweating smoker — ECG before antacid discharge.[1]

The killers that mimic ACS — exclude the dissection first

Several life-threatening mimics must be ruled out before you commit to ACS therapy, because antiplatelets and anticoagulants can be catastrophic if the true diagnosis is one of them. This table is the cornerstone of the chest-pain SAQ:[1]

Life-threatening mimics of ACS — distinguishing features
DiagnosisDistinguishing featuresWhy it matters
Aortic dissectionTearing, migrating pain to the back; pulse or BP differential between arms; new aortic regurgitation murmur; widened mediastinum on CXRAnticoagulating a dissection can be fatal — exclude FIRST
Pulmonary embolismPleuritic pain, dyspnoea, tachycardia, VTE risk factors; sinus tachycardia with right-heart strain on ECGNormal coronary-territory ECG; anticoagulation intent differs
Tension pneumothoraxSudden dyspnoea and pleuritic pain; tracheal deviation, hyperresonance, absent breath sounds one side; hypoxia, hypotensionNeeds immediate needle decompression, not antithrombotics
Pericarditis or tamponadePleuritic, positional pain eased by sitting forward; diffuse saddle-shaped ST elevation with PR depression; pericardial rub; Beck triad if tamponadeDiffuse, not territorial, ST changes distinguish pericarditis from STEMI
Oesophageal rupture (Boerhaave)Vomiting then severe pain; subcutaneous emphysema; hydropneumothorax on CXRSurgical emergency; anticoagulation harmful
Oesophageal spasm or refluxCan mimic ischaemic pain closely; relieved by GTN if spasm; postprandialA trial of antacid must NEVER delay ACS work-up
[1]

The single differential to exclude clinically before treatment is aortic dissection: tearing, migrating pain to the back, a pulse or blood-pressure differential over 20 mmHg between limbs, a new aortic regurgitation murmur, a widened mediastinum on chest X-ray. Anticoagulating a dissection is potentially fatal, so the bundle waits until that possibility is addressed.[1]

Musculoskeletal pain, herpes zoster (where the pain can precede the rash), biliary colic (which can mimic inferior MI, and vice versa), and panic attacks round out the broader list — none of them is a diagnosis you may make before excluding the killers.[1]

The bedside round — look for complications, not the diagnosis

Examination in suspected ACS rarely provides a diagnostic sign; its job is to detect complications and assess haemodynamics. Run the focused cardiovascular examination in this order:[1]

  • Pulse — rate and rhythm. Tachycardia points to hypovolaemia, pain, or arrhythmia; bradycardia points to conduction disease, especially in inferior MI from RCA occlusion of the AV-nodal artery.
  • Blood pressure in BOTH arms — a differential over 20 mmHg raises dissection.
  • JVP — raised in right-heart failure or right ventricular infarction.
  • Heart sounds — an S3 signals ventricular dysfunction; a new murmur is a red flag for a mechanical complication (pansystolic suggests papillary muscle rupture or VSD).
  • Lungs — crackles mean pulmonary oedema.
  • Peripheries — cool, shut-down skin means cardiogenic shock.[1]

The Killip classification grades heart-failure severity at presentation and predicts mortality directly — reproduce it verbatim:[25]

Killip classification — heart failure severity at presentation
Killip classClinical findingsIn-hospital mortality, primary-PCI era
INo clinical signs of heart failure2.4%
IIBibasal crackles, S3 gallop, or raised JVP7%
IIIFrank pulmonary oedema19%
IVCardiogenic shock — SBP under 90 plus poor perfusionExcluded from that analysis; in MI-related shock treated with early revascularisation, ~50% at 12 months
[25] [7]

Higher Killip class escalates the urgency of monitoring and revascularisation and feeds the GRACE score. The bedside definition of cardiogenic shock — hypotension (systolic BP under 90 mmHg), signs of poor perfusion (cold clammy skin, oliguria, altered sensorium), and pulmonary oedema or low cardiac output — marks the patient who needs immediate, not deferred, revascularisation.[1]

Ten minutes, ninety minutes, two hours — the time-critical numbers

These are the numbers that win or lose an ACS stem, and they are non-negotiable.[1]

Acute coronary syndrome — the time-critical numbers

Under 10 minFMC-to-ECGECG obtained at first medical contact, interpreted within 10 minutes
Under 90 minFMC-to-devicePrimary PCI target for STEMI presenting to a PCI-capable hospital
Under 120 minPCI-vs-lysis cutoffTransfer target; if PCI cannot be delivered in time, fibrinolyse
Under 10 minDiagnosis-to-lytic bolusESC target once STEMI is diagnosed and PPCI is not deliverable in time
0 h / 1 hhs-troponin algorithmESC 0 h/1 h (best) or 0 h/2 h; 0 h/3 h as the fallback
[1] [18] [19]

The 12-lead ECG, obtained and interpreted within 10 minutes of first medical contact, is the single most important initial test — it separates STEMI (reperfuse now, regardless of biomarkers) from everything else. High-sensitivity cardiac troponin is then run on a rapid algorithm: the ESC 0-hour/1-hour (or 0/3-hour) protocol triages patients into rule-out, observe, or rule-in bands based on absolute values and the magnitude of change — a rise/fall with at least one value above the 99th-percentile URL, in the right clinical context, defines infarction. The 0/1-hour pathway lets you safely discharge low-risk patients within an hour of arrival.[1]

Interpret troponin in context, always. Chronic stable elevations occur in renal failure; a small rise with a flat (non-rising) pattern means chronic injury, not acute infarction.[1]

Two named risk scores are essential for NSTE-ACS, reproduced exactly as the examiner expects:[1]

NSTE-ACS risk scores — reproduced verbatim
ScoreComponentsWhat it predicts and thresholds
GRACE (2.0)Age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at admission, ST deviation, elevated biomarkersIn-hospital and 6-month mortality; high-risk over 140 means early invasive within 24 h
TIMI (UA/NSTEMI)7 points: age at least 65; at least 3 CAD risk factors; known CAD stenosis at least 50 percent; aspirin in past 7 days; at least 2 anginal episodes in 24 h; ST deviation at least 0.5 mm; elevated biomarker14-day death, MI or urgent revascularisation; event rate climbs from 4.7 percent at 0–1 points to 40.9 percent at 6–7
HEARTHistory, ECG changes, Age, Risk factors, Troponin (each 0/1/2)Major adverse cardiac event at 6 weeks; low 0–3 (1.7 percent), medium 4–6 (16.6 percent), high 7–10 (50.1 percent)
[1] [21] [22]

Adjunct investigations: chest X-ray (pulmonary oedema, a widened mediastinum raising dissection, pneumothorax); bedside echocardiography (regional wall-motion abnormality confirming ischaemia, ejection fraction, mechanical complications, effusion); bloods (FBC, U&E, glucose, fasting lipids); and coronary angiography, the definitive investigation and the gateway to PCI.[1]

MONA-B plus anticoagulant — the first-contact bundle

FigureThe management spine: immediate antiplatelet/anticoagulant loading for every patient, then a fork on the ECG — reperfusion for STEMI, risk-stratified invasive timing for NSTE-ACS — converging on lifelong secondary prevention. (AI-generated educational figure.)

Every suspected ACS patient gets the same bundle at first contact, with one modern correction examiners now test: oxygen only if the patient is hypoxaemic.[10]

Immediate first-contact bundle for every suspected ACS

  1. 1

    Continuous cardiac monitoring plus IV access plus defibrillator at bedside

    The malignant arrhythmias of the first hours are fully reversible with immediate defibrillation — the pads must be ready

  2. 2

    Immediate 12-lead ECG at first contact

    The single most decisive test — separates STEMI (reperfuse now) from NSTE-ACS (risk-stratify)

  3. 3

    Oxygen ONLY if hypoxaemic — NOT routinely

    DETO2X-AMI: routine supplemental oxygen in suspected MI with an oxygen saturation of 90 percent or higher did not reduce 1-year all-cause mortality

  4. 4

    Aspirin chewed at first contact, then daily low-dose maintenance

    The best-evidenced single intervention in suspected acute MI — 26 fewer deaths per 1000 in the first 35 days, benefit still present at 10 years (ISIS-2)

  5. 5

    P2Y12 inhibitor loading — ticagrelor 180 mg then 90 mg twice daily, prasugrel 60 mg then 10 mg daily when PCI is planned, or clopidogrel 300 mg then 75 mg daily

    Give as soon as ACS is suspected and bleeding excluded — after dissection is considered (PLATO, TRITON-TIMI 38, CURE)

  6. 6

    Parenteral anticoagulant — fondaparinux 2.5 mg daily or enoxaparin 1 mg/kg twice daily (intravenous unfractionated heparin in the intended-invasive strategy)

    OASIS-5: similar ischaemic protection with half the major bleeding on fondaparinux; SYNERGY: enoxaparin non-inferior to UFH

  7. 7

    Analgesia — IV opioid titrated in small doses, with an antiemetic

    Treat the pain without over-sedating

  8. 8

    Sublingual GTN for ongoing pain; beta-blocker if pain or rate control needed

    AVOID nitrates in RV infarct, hypotension, recent PDE-5 use; AVOID beta-blockers in acute HF or cardiogenic shock

[10] [2] [5] [13] [4] [11] [12]

Two warnings recur in exams. First, routine oxygen in a normoxic patient does not help — DETO2X-AMI randomised 6629 patients with suspected MI and oxygen saturation of 90 percent or higher to oxygen or ambient air and found no difference in 1-year mortality (5.0 vs 5.1 percent), so oxygen is reserved for the hypoxaemic. Second, treat the pain, but do not over-sedate.[10]

Aspirin deserves its own sentence. The ISIS-2 trial randomised 17,187 patients with suspected acute MI in a 2x2 factorial design to intravenous streptokinase (1.5 MU over one hour), one month of oral aspirin (162 mg daily), both, or neither. In the first 35 days streptokinase saved 29 lives per 1000 treated and aspirin saved 26 per 1000 — independent early gains that persisted, the streptokinase benefit still standing at 23 fewer deaths per 1000 after 10 years, and the early advantage of the combination "seemed to persist long term".[2]

Ventricular fibrillation or pulseless VT in the first hours is the leading cause of pre-hospital death in acute MI, fully reversible with immediate defibrillation per advanced life support. The monitor pads and the bedside defibrillator exist for precisely this.[1]

The 120-minute fork — primary PCI or fibrinolysis

After the bundle, management forks on the ECG. STEMI goes to emergency reperfusion; NSTE-ACS goes to risk-stratified invasive timing.[1]

STEMI reperfusion pathway

  1. 1

    PRIMARY PCI whenever it can be delivered in time — including by transfer

    DANAMI-2: transferring referral-hospital patients to a PCI centre beat on-site fibrinolysis (8.5 vs 14.2 percent death/reinfarction/disabling stroke at 30 days), provided the transfer took two hours or less

  2. 2

    If primary PCI cannot be delivered in time — fibrinolysis with bolus tenecteplase

    STREAM: bolus tenecteplase (amended to half dose at 75 years or older) with clopidogrel and enoxaparin, then transport to a PCI-capable hospital, matched primary PCI in early presenters

  3. 3

    After lysis: emergency angiography if fibrinolysis fails, otherwise routine angiography 6 to 24 hours after randomisation

    The pharmacoinvasive bridge — 36.3 percent of STREAM lysis patients still needed emergency angiography

  4. 4

    Antithrombotic support through reperfusion

    Aspirin plus heparin, aPTT-guided (ASSENT-2); ticagrelor-based DAPT for the following year (PLATO)

[16] [9] [8] [5]

Primary PCI is the preferred strategy when it can be delivered in time — DANAMI-2 found a transfer-for-angioplasty strategy superior to on-site fibrinolysis (driven mainly by reinfarction, 1.6 vs 6.3 percent), provided the transfer took two hours or less; 96 percent of transferred patients reached the invasive centre within two hours. When PCI cannot be delivered in that window, early fibrinolysis with bolus tenecteplase plus transfer for timely angiography is effective in early presenters (STREAM). The fibrinolytic agents:[16][9]

Fibrinolytic agents — dosing
AgentDoseNote
Tenecteplase (TNK-tPA)Single weight-based IV bolus, 30 to 50 mg according to bodyweightASSENT-2: 30-day mortality identical to alteplase (6.18 vs 6.15 percent) with fewer non-cerebral bleeds — the single bolus eases and speeds treatment in and out of hospital
Alteplase (rt-PA)Rapid (front-loaded) infusion, total 100 mg or lessThe accelerated regimen used in ASSENT-2 and DANAMI-2; infusion-based rather than bolus
Streptokinase1.5 million units IV over one hourThe ISIS-2 regimen — 29 fewer deaths per 1000 in the first 35 days; the cheapest option where newer agents are unaffordable
[8] [2] [16]

Absolute contraindications to fibrinolysis are any prior intracranial haemorrhage, a known structural cerebral vascular lesion or a malignant intracranial neoplasm, suspected aortic dissection, active bleeding or a bleeding diathesis, significant closed-head or facial trauma within 3 months, intracranial or intraspinal surgery within 2 months, and severe uncontrolled hypertension. Recent ischaemic stroke also bars lysis — prior ischaemic stroke becomes only a relative contraindication beyond 3 months. These patients are transferred for PCI even if delayed.[18]

NSTE-ACS — a risk-stratification problem, not a plumbing emergency

NSTE-ACS is not a plumbing emergency. Angiography timing is chosen from risk features and a validated score, and the TIMACS trial is the evidence: early intervention (within 24 hours) did not beat delayed intervention for the primary outcome overall (9.6 vs 11.3 percent, P=0.15) but cut death, MI or refractory ischaemia by 28 percent (9.5 vs 12.9 percent) and improved the primary outcome in the highest-risk third (HR 0.65).[6]

NSTE-ACS invasive-strategy timing (ESC 2023)
Risk categoryDefining featuresAngiography timing
Very high riskHaemodynamic instability or cardiogenic shock; recurrent or refractory chest pain despite medical treatment; life-threatening arrhythmia; mechanical complications; acute heart failure clearly related to the NSTE-ACSImmediate — emergency angiography, as soon as possible
High riskConfirmed NSTEMI on the hs-cTn algorithm; GRACE score above 140; dynamic ST-segment or T-wave changes; transient ST elevationInpatient invasive strategy recommended; early invasive (within 24 h) should be considered
Neither very high nor high riskClinical suspicion of NSTE-ACS with non-elevated troponin, or troponin elevated but not meeting MI criteriaInpatient invasive strategy if suspicion of unstable angina is high; otherwise selective invasive after ischaemia testing or CT coronary angiography
[1] [6]

DAPT and anticoagulation — name the drug, the dose, the trial

Dual antiplatelet therapy is the foundation: aspirin plus a P2Y12 inhibitor, for 12 months in PLATO and 3 to 12 months in CURE, agent chosen by efficacy, bleeding risk, cost, and access. The landmark trials are core exam material:[5][4]

P2Y12 inhibitor comparison and landmark trials
P2Y12 inhibitorLoading and maintenanceLandmark evidence
Ticagrelor (preferred)180 mg load then 90 mg twice dailyPLATO — vascular death, MI, or stroke 9.8 vs 11.7 percent (HR 0.84) versus clopidogrel, without an increase in overall major bleeding but with more non-procedure-related bleeding
Clopidogrel300 mg load then 75 mg daily (300-to-600 mg loads used across trials)CURE — aspirin plus clopidogrel (300 mg then 75 mg) cut cardiovascular death, MI, or stroke to 9.3 vs 11.4 percent versus aspirin alone in NSTE-ACS, at the cost of more major bleeding
Prasugrel (PCI-planned only)60 mg load then 10 mg dailyTRITON-TIMI 38 — ischaemic events 9.9 vs 12.1 percent versus clopidogrel including less stent thrombosis, but more major and fatal bleeding and no mortality difference
[5] [4] [13]

Ticagrelor (PLATO) and prasugrel (TRITON-TIMI 38) reduced ischaemic events versus clopidogrel at the cost of more bleeding, and are preferred where affordable and not contraindicated; clopidogrel remains the workhorse in cost-constrained settings and where bleeding risk or an oral anticoagulant dominates.[5][4][13]

Parenteral anticoagulation comes straight from the head-to-head trials: OASIS-5 randomised 20,078 ACS patients to fondaparinux 2.5 mg daily versus enoxaparin 1 mg/kg twice daily — ischaemic protection was similar, but fondaparinux halved major bleeding (2.2 vs 4.1 percent) and reduced deaths at 30 days (295 vs 352) and 180 days. In the intended-early-invasive setting, SYNERGY found subcutaneous enoxaparin non-inferior to intravenous unfractionated heparin, at the price of a modest excess of TIMI major bleeding (9.1 vs 7.6 percent).[11][12]

The five pillars of secondary prevention

Every ACS survivor leaves hospital on the same disease-modifying bundle — as examinable as the acute ladder:[1]

Secondary-prevention bundle after ACS

  1. 1

    Dual antiplatelet therapy — aspirin plus a P2Y12 inhibitor

    Twelve months of ticagrelor in PLATO; clopidogrel added to aspirin for 3 to 12 months in CURE

  2. 2

    High-intensity statin

    Atorvastatin 80 mg daily beat pravastatin 40 mg after ACS in PROVE-IT — median LDL 62 mg/dL (1.60 mmol/L), 16 percent fewer events

  3. 3

    Beta-blocker

    Oral, titrated — part of post-infarction therapy since the thrombolytic era (the background standard in AIRE)

  4. 4

    ACE-inhibitor after infarction with heart failure

    Ramipril started day 3 to 10 post-MI cut all-cause mortality to 17 vs 23 percent (AIRE)

  5. 5

    Mineralocorticoid receptor antagonist with ventricular dysfunction and heart failure

    Eplerenone 25 mg daily initially, titrated to a maximum of 50 mg, on top of optimal therapy (EPHESUS)

  6. 6

    Smoking cessation plus cardiac rehabilitation plus risk-factor control

    BP, glucose, and lipid review at every visit

[5] [4] [15] [17] [14]

This bundle, plus lifestyle (Mediterranean diet, regular exercise, weight management, alcohol moderation), is what drives the long-term reduction in recurrent events. Cardiac rehabilitation — structured exercise, education, and risk-factor modification — cuts mortality and rehospitalisation and should be offered to every eligible patient.[1]

Escalation — cardiogenic shock: vasopressor and inotropic support (noradrenaline as the vasopressor, dobutamine for a low-output state) and urgent revascularisation. Mechanical circulatory support (intra-aortic balloon pump, percutaneous ventricular assist, ECMO) is considered in refractory cases — though IABP-SHOCK II showed no mortality benefit from routine balloon pumping in MI-related cardiogenic shock at 30 days or 12 months (52 vs 51 percent dead at 12 months), so the IABP is now selective, not default.[7] Suspected mechanical complications (VSD, papillary muscle rupture, free-wall rupture) demand urgent echocardiography and cardiothoracic surgical referral.[1]

The subtypes that bite

Right ventricular infarction complicates inferior STEMI (proximal RCA occlusion cutting the RV marginal branches). The classic triad — hypotension, clear lung fields, and a raised JVP — is confirmed by ST elevation in V3R–V4R. Management is the opposite of left-sided failure: fluid loading to maintain RV preload (the RV is preload-dependent), with nitrates and diuretics avoided because they drop preload-dependent RV output. A nitrate-induced drop in BP during treatment of an inferior STEMI should immediately raise this possibility.[1]

Posterior wall MI is missed because the standard 12 leads do not directly visualise the posterior wall — it shows as tall R waves and ST depression in V1–V2 (a mirror of posterior ST elevation). Confirm with posterior leads V7–V9, then treat as a STEMI-equivalent and activate reperfusion.[1]

MI in the setting of LBBB — the broad, discordant QRS obscures the usual ST criteria. The Sgarbossa criteria (and the more sensitive Smith-modified version using a proportional ST/S ratio) identify ischaemic ST changes discordant with the QRS. A new LBBB with ischaemic symptoms is a STEMI-equivalent regardless.[1]

Spontaneous coronary artery dissection (SCAD) — a tear in the arterial wall creating a false lumen that compresses the true lumen. It predominantly affects young women without traditional risk factors, often peripartum or with fibromuscular dysplasia. Managed differently from Type 1 ACS: conservative therapy is preferred where the artery is patent (the dissection often heals spontaneously); stenting a dissection plane can extend it.[1]

Coronary vasospasm (Prinzmetal or variant angina) — transient, reversible ST elevation at rest, classically in the early morning, relieved by nitrates and calcium-channel blockers. The plaque may be non-critical; the mechanism is spasm. Manage with calcium-channel blockers and nitrates, avoiding beta-blockers (unopposed alpha vasoconstriction).[1]

An initially normal ECG with suspected ACS — repeat every 15–30 minutes, record right-sided (V3R–V4R) and posterior (V7–V9) leads in inferior or borderline cases, and chase serial troponin. Circumflex occlusion is the classic ECG-silent STEMI; if suspicion is high and the ECG normal, bedside echocardiography showing a regional wall-motion abnormality may reveal the territory.[1]

When the MI kills you later — complications by clock

Complications separate by timing, and the timing is the most examinable single fact about each. The clock matters more than the murmur.[1]

Post-MI complications — when they strike

  1. 0–24 hReperfusion arrhythmias and sudden death
    Ventricular fibrillation is the leading cause of sudden death in the first hours — fully reversible with immediate defibrillation. Accelerated idioventricular rhythm ('reperfusion arrhythmia') is usually benign.
  2. 0–72 hCardiogenic shock and conduction disease
    Cardiogenic shock from extensive myocardial loss (often anterior or large infarct); Mobitz II or complete heart block from AV-nodal ischaemia in inferior MI.
  3. First 24 h to first weekMechanical complications
    Ventricular septal rupture typically within the first 24 hours (new loud systolic murmur, heart failure or shock); free-wall rupture typically from 24–48 hours to the first week (sudden collapse and tamponade); papillary muscle rupture peaking at 2–7 days (acute severe MR and pulmonary oedema).
  4. Days 2 to 10 weeksPericardial complications
    Acute pericarditis (early, directly from transmural infarction) and Dressler syndrome (delayed, autoimmune, 2–10 weeks).
  5. Weeks to monthsRemodelling and aneurysm
    Adverse ventricular remodelling leads to ischaemic cardiomyopathy and chronic heart failure; LV aneurysm (persistent ST elevation, mural thrombus, systemic embolism risk).
[1]

The three mechanical complications cluster in the first week, when necrosis has softened the myocardium, and each carries a characteristic sign — so a new pansystolic murmur days after MI is a red flag demanding urgent echocardiography and surgical referral. Papillary muscle rupture peaks at 2–7 days and usually involves the posteromedial muscle (RCA supply alone, versus the anterolateral's dual LAD/LCx supply), producing acute severe mitral regurgitation with sudden pulmonary oedema; repair or replace the valve. Ventricular septal rupture usually declares itself within the first 24 hours of a STEMI, with a harsh pansystolic murmur and thrill at the lower left sternal border, a left-to-right shunt on colour Doppler and biventricular failure; it needs emergency surgical repair. Free-wall rupture typically strikes from 24–48 hours out to the first week — commoner in older women, first infarcts and anterior infarcts — producing sudden cardiac tamponade with electromechanical dissociation, and is often fatal.[29]

Dressler syndrome — an autoimmune post-MI pericarditis presenting 2–10 weeks after the index event with fever, pleuritic chest pain, a pericardial rub, and a pericardial effusion, with raised inflammatory markers. Managed with NSAIDs and colchicine; steroids are reserved for refractory cases. It is distinct from the acute pericarditis of the first few days, which reflects direct transmural inflammation.[1]

The recurring pitfalls every candidate must name:[1]

  • Failing to exclude aortic dissection before anticoagulating.
  • Attributing epigastric pain to dyspepsia in a diabetic who is actually infarcting.
  • Withholding reperfusion because the ECG is "borderline" — repeat it, record posterior and right-sided leads, look for STEMI-equivalents.
  • Relying on a single negative troponin too early in the rise/fall curve — the 0/1-hour or 0/3-hour algorithm exists to avoid exactly this.
  • Missing right ventricular infarction, giving nitrates, and precipitating profound hypotension.
  • Treating a Type 2 MI with loading DAPT and a dash to angiography instead of treating the precipitant.[1]

How ACS patients come to harm — the preventable list

  • Death from an unrecognised aortic dissection that was anticoagulated as "atypical MI" — the preventable death.[1]
  • Inferior STEMI given nitrates that was a right ventricular infarct, ending in profound hypotension.[1]
  • A posterior STEMI read as "NSTEMI with ST depression", delaying reperfusion.[1]
  • A Type 2 MI in sepsis loaded with DAPT and sent for angiography, with a bleeding complication and no ischaemic benefit.[3]
  • A mechanical complication on day 4 misread as "just heart failure" when a new murmur was the clue.[1]
  • Aspirin omitted for a "possible gastritis" chest pain, or for a soft, non-absolute contraindication.[2]
  • A large anterior infarct left without an echocardiogram, missing an LV thrombus.[1]
  • DAPT stopped at three months because the patient felt well, with stent thrombosis the result.[1]

Prognosis, disposition, and the score that sets both

Mortality after ACS is set by infarct size, time to reperfusion, baseline risk (age, comorbidity, diabetes, CKD), Killip class at presentation, the GRACE score, and any mechanical or arrhythmic complication. Thirty-day mortality after STEMI treated with fibrinolysis was about 6 percent in ASSENT-2; in the Indian CREATE registry, where only 8 percent of STEMI patients reached PCI, 30-day mortality was 8.6 percent for STEMI against 3.7 percent for NSTEMI or unstable angina. Early mortality is therefore higher in STEMI; NSTE-ACS catches up over the following months because that population is older and more comorbid with multivessel disease.[8][23]

Killip class at the bedside still predicts in-hospital mortality and drives disposition — CCU or ICU for class III or IV. In the primary-PCI era:[25]

ClassClinical findingsIn-hospital mortality with primary PCI
INo clinical HF2.4 percent
IIMild HF — S3, basal rales, raised JVP7 percent
IIIAcute pulmonary oedema19 percent
IVCardiogenic shockExcluded from that analysis; around 50 percent dead at 12 months even with early revascularisation
[25] [7]

GRACE estimates in-hospital and 6-month mortality from age, heart rate, systolic BP, creatinine, Killip class, cardiac arrest at admission, ST deviation, and elevated biomarkers. The thresholds that govern invasive timing in NSTE-ACS:[1]

  • GRACE over 140 — a high-risk criterion in the 2023 ESC guideline — inpatient invasive strategy, with early invasive (within 24 hours) to be considered.
  • GRACE 140 or below — not by itself a high-risk criterion; timing then follows the other high-risk features (confirmed NSTEMI, dynamic ST/T changes, transient ST elevation), and where none is present a selective invasive approach after ischaemia testing or CT coronary angiography is appropriate.[1]

TIMI (0–7) is simpler at the bedside: age at least 65, at least 3 CAD risk factors, known CAD stenosis at least 50 percent, aspirin in the past 7 days, at least 2 anginal episodes in 24 hours, ST deviation at least 0.5 mm, positive biomarker — each one point. The 14-day rate of death, MI or urgent revascularisation rises from 4.7 percent at 0–1 points to 40.9 percent at 6–7.[21]

Worked disposition stems:[1]

  • Killip IV anterior STEMI — a 62-year-old, anterior STEMI, BP 78/50, cool extremities, pulmonary oedema: activate the cath lab now, CCU or ICU after PCI, consider mechanical circulatory support if shock is refractory, do not reach routinely for the IABP. Mortality without revascularisation is catastrophic.
  • Low-risk NSTEMI — a 48-year-old with a troponin rise, normal ECG after pain resolution, GRACE 80, no ongoing pain: monitored ward, DAPT plus anticoagulant, early cardiology review; invasive strategy often during the index admission but not emergent if truly low risk and stable.
  • Post-lysis rural transfer — after successful fibrinolysis (ST resolution over 50 percent at 60–90 minutes, pain free), transfer for routine early angiography within 2–24 hours; if lysis failed (persistent ST elevation or pain at 60–90 minutes), rescue PCI.[1][18]

Recurrent event risk stays elevated indefinitely. Post-MI LV impairment, incomplete revascularisation, ongoing smoking, and DAPT non-adherence drive early stent thrombosis and late events. LV thrombus after a large anterior MI needs anticoagulation (typically 3 months) with the antiplatelet strategy individualised — echo surveillance is mandatory after large anterior infarcts.[1]

Special populations — presentation, reperfusion, and bleeding risk all change

Examiners use these scenarios heavily on NEET-PG and INICET.[1]

Diabetes mellitus. Atypical and silent infarction is the trap — a diabetic with unexplained dyspnoea, nausea, fatigue, or epigastric discomfort still needs an immediate ECG. Otherwise the pathway is unchanged: DAPT plus anticoagulation, and an invasive strategy timed to risk — TIMACS sent the high-risk third of NSTE-ACS patients to angiography within 24 hours and their primary outcome improved (HR 0.65).[6]

Elderly and frail. They present with dyspnoea, syncope, delirium, a fall, or epigastric pain more than classic crushing pain. Bleeding risk on DAPT and anticoagulation is higher, so use PRECISE-DAPT and ARC-HBR concepts to individualise DAPT duration (often 1–3 months of dual therapy then de-escalation). Prasugrel is contraindicated after prior stroke or TIA; at 75 years or older or under 60 kg the maintenance dose is cut to 5 mg daily (or the drug avoided), because TRITON-TIMI 38 bought its ischaemic gain with more major and fatal bleeding. Prefer radial access, creatinine-adjusted anticoagulants, and shorter triple therapy if on an oral anticoagulant.[18][13]

Women and pregnancy-associated MI. Women present later, more atypically, and receive delayed reperfusion more often — a systems failure examiners flag. SCAD is a leading cause of MI in pregnancy and the peripartum period and in young women without traditional risk factors, often managed conservatively if stable. In pregnancy, protect the fetus (left lateral tilt, abdominal shielding, prefer echocardiography), because fibrinolysis is relatively contraindicated (placental abruption) and PCI is preferred when available. MINOCA (MI with non-obstructive coronaries) is more often diagnosed in women and needs cardiac MRI — consider spasm, plaque erosion, myocarditis, Takotsubo.[1]

Chronic kidney disease. Interpret troponin as a dynamic pattern rather than a single absolute value, and individualise the antithrombotic balance: SYNERGY's enoxaparin-versus-UFH comparison already carried a modest excess of TIMI major bleeding (9.1 vs 7.6 percent), and fondaparinux halved major bleeding versus enoxaparin in OASIS-5 (2.2 vs 4.1 percent) — renal impairment moves those balances further, so minimise contrast at angiography and hydrate where volume allows.[12][11]

Patients on oral anticoagulation (for example AF). After PCI for ACS, the default modern strategy is short triple therapy (OAC plus aspirin plus clopidogrel) for up to 1 week to 1 month, then dual therapy (OAC plus clopidogrel) to 6–12 months, then OAC monotherapy. Prefer clopidogrel as the P2Y12 with an OAC (less bleeding than ticagrelor or prasugrel), prefer a DOAC over warfarin when eligible, and always reassess HAS-BLED-style modifiers and add gastroprotection with a PPI.[1]

Cocaine and stimulant-associated ACS. The mechanism is vasospasm with or without plaque rupture plus a hyperadrenergic state. Give benzodiazepines early for agitation and hypertension; nitrates and calcium-channel blockers for spasm. Avoid pure beta-blockers early (theoretical unopposed alpha vasoconstriction) — if beta-blockade is needed after vasodilation, labetalol is sometimes used carefully. Still consider angiography if STEMI criteria are met — not all cocaine chest pain is spasm alone.[1]

Cardiogenic shock and post-arrest. Emergency revascularisation remains the cornerstone (SHOCK trial logic). Routine IABP is not indicated (IABP-SHOCK II) — reserve mechanical circulatory support for selected centres and phenotypes. Targeted temperature management after ROSC per local protocol; early angiography after out-of-hospital cardiac arrest with ST elevation is standard, and individualised without it.[7]

The trials that changed practice

The 2023 ESC Guidelines unified the previously separate STEMI and NSTE-ACS documents into a single "one syndrome" guideline, reflecting shared pathophysiology and overlapping early management. Headline recommendations: the 0 h/1 h high-sensitivity troponin algorithm (0 h/2 h second-best, 0 h/3 h as fallback), 12 months of DAPT with prasugrel or ticagrelor as the default after PCI, radial-artery access for PCI, complete revascularisation in STEMI multivessel disease, and de-escalation or abbreviation of antithrombotic therapy in patients whose bleeding risk dominates.[1][28]

The landmark trials an examiner expects you to cite, and what each changed:[1]

ISIS-2 (1988; 10-year follow-up 1998)

Population: 17,187 patients with suspected acute myocardial infarction, 2x2 factorial

Key finding

In days 0-35 streptokinase saved 29 lives per 1000 and aspirin 26 per 1000; the gains persisted, with 23 fewer deaths per 1000 on streptokinase still evident at 10 years, and the combination's early benefit 'seemed to persist long term'.

[2]

CURE (2001)

Population: Over 12,500 patients with NSTE-ACS

Key finding

20 percent relative reduction in cardiovascular death, MI, or stroke; increased major bleeding.

[4]

PLATO (2009)

Population: Over 18,600 patients with ACS (STEMI and NSTE-ACS)

Key finding

Primary endpoint (vascular death, MI, or stroke) 9.8 vs 11.7 percent — a 16 percent relative reduction (HR 0.84) — without an increase in overall major bleeding but with more non-procedure-related bleeding.

[5]

TIMACS (2009)

Population: Over 3,000 patients with NSTE-ACS

Key finding

Primary outcome (death, MI or stroke at 6 months) 9.6 vs 11.3 percent, not significant (HR 0.85, P=0.15); the secondary composite of death, MI or refractory ischaemia fell 28 percent (9.5 vs 12.9 percent, HR 0.72). Early intervention improved the primary outcome in the highest-risk third (HR 0.65) but not in the other two thirds (HR 1.12).

[6]

IABP-SHOCK II (2012; final 12-month 2013)

Population: 600 patients with acute MI and cardiogenic shock planned for early revascularisation

Key finding

No difference in 30-day or 12-month mortality.

[7]

Regional deltas — the diagnostic and management framework (ECG, troponin, DAPT, timely reperfusion) is globally consistent, but resource-dependent choices differ:[1]

UK

NICE NG185 (chest pain of recent onset) recommends the high-sensitivity troponin 0/3-hour rule-out pathway and CT coronary angiography for low-probability patients. Primary PCI networks are mature; fibrinolysis is rarely used.[1]

US

ACC and AHA guidelines target primary PCI with first-device activation within 90 minutes of first medical contact (120 minutes for transfer patients), with fibrinolysis when PCI cannot be delivered in that window; DAPT defaults to ticagrelor or prasugrel.[18]

ANZ

Australian and New Zealand cardiac networks use a hub-and-spoke model with systematic transfer for primary PCI; cardiologists invoke the ESC and ACC/AHA evidence locally.[1]

In India (the NEET-PG and INICET context), timely primary PCI access is uneven. The CREATE registry of 20,937 Indian ACS admissions found that only 8.0 percent of STEMI patients underwent PCI, while 58.5 percent received a thrombolytic — 96.3 percent of it streptokinase — with a median hospital-to-thrombolysis time of 50 minutes; 30-day STEMI mortality was 8.6 percent, and poorer patients received fewer evidence-based treatments and died more often (8.2 vs 5.5 percent). Generic clopidogrel is often favoured over ticagrelor or prasugrel on cost, even though the more potent agents are preferred where affordable.[23]

[23] [1]

Controversies to name calmly: the routine-oxygen question (answered — no reduction in 1-year mortality in normoxic patients); the morphine–P2Y12 interaction (a measurable pharmacokinetic effect, uncertain clinical impact); complete revascularisation versus culprit-only PCI in STEMI (COMPLETE: cardiovascular death or MI 7.8 vs 10.5 percent at a median 3 years, HR 0.74); and the optimal DAPT duration and de-escalation strategy (guided by bleeding versus ischaemic risk).[10][28][1]

The mantra, and the mnemonic

MONA-B

  • MMorphine (small IV doses, with an antiemetic — use sparingly)
  • OOxygen (only if hypoxaemic — routine oxygen at a saturation of 90 percent or higher did not reduce 1-year mortality in DETO2X-AMI)
  • NNitrates (sublingual GTN; AVOID in RV infarct, hypotension, recent PDE-5 use)
  • AAspirin (chewed at first contact, then daily maintenance — 26 fewer deaths per 1000 in the first 35 days, ISIS-2)
  • BBeta-blocker (AVOID in acute HF or cardiogenic shock)
[10] [2]

And never forget the P2Y12 inhibitor and the parenteral anticoagulant — they complete the immediate loading the mnemonic's five letters leave out.[1]

TIMI

  • TTroponin elevated
  • IIschaemia — at least 2 anginal episodes in 24 h; plus age at least 65, at least 3 risk factors, known CAD at least 50 percent, aspirin in past 7 days
  • MMinor ST deviation (at least 0.5 mm)
  • IIschaemic evidence on ECG or biomarker — each component 1 point, 0–7 total
[21]

The mantra: immediate ECG, chewed aspirin, open the artery — everything else is refinements.[1][2]

Ward-round test — three stems, thirty seconds each

Stem 1 — the man from the top of the topic (answer)Show

The 58-year-old smoker with anterior ST elevation at 3am. The PCI centre is 3 hours away. What do you do in the next 30 minutes? Model: This is STEMI — a three-hour transfer sits outside the two-hour window in which DANAMI-2 showed transfer-for-PCI beats on-site lysis, so fibrinolyse with a single weight-based bolus of tenecteplase 30 to 50 mg (ASSENT-2), after the immediate bundle (chewed aspirin, a P2Y12 inhibitor, a parenteral anticoagulant) and after excluding contraindications to lysis and the clinical possibility of dissection. Then pursue the STREAM strategy — transfer to a PCI-capable hospital for emergency angiography if fibrinolysis fails, otherwise routine angiography 6 to 24 hours after randomisation.[16][8][9]

Stem 2 — the inferior STEMI that drops its BP (answer)Show

An inferior STEMI becomes hypotensive the moment you give sublingual GTN. Lung fields are clear, JVP is raised. What happened, and what do you do? Model: This is right ventricular infarction — the nitrate dropped RV preload, and the RV is preload-dependent. Record right-sided leads V3R–V4R for ST elevation to confirm. No nitrates, no diuretics — give fluid boluses to restore RV preload. This is the classic "what not to do" trap, and it is why you record V3R–V4R in every inferior STEMI before reaching for the GTN.[1]

Stem 3 — the septic patient with a troponin bump (answer)Show

A 72-year-old on the ward with sepsis, heart rate 120, known coronary disease, has a troponin of 200 ng/L and a normal ECG. The registrar wants to load DAPT and call the cath lab. What is the right call? Model: This is Type 2 MI (supply-demand mismatch from tachycardia and hypotension on fixed CAD), or acute myocardial injury without ischaemic evidence — neither is the plaque-rupture pathway. Treat the precipitant: source control, fluids, oxygen, and rate control. Loading DAPT and rushing to angiography is the recurring trainee error that exposes the patient to bleeding without addressing the cause. Reserve the Type 1 pathway for ischaemic symptoms, new ECG changes, or a clear rise/fall troponin pattern in the right context.[3]

References29Show
  1. [1]Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes Eur Heart J, 2023.PMID 37622654
  2. [2]Baigent C, Collins R, Appleby P, et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group BMJ, 1998.PMID 9563981
  3. [3]Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018) J Am Coll Cardiol, 2018.PMID 30153967
  4. [4]Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med, 2001.PMID 11519503
  5. [5]Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med, 2009.PMID 19717846
  6. [6]Mehta SR, Granger CB, Boden WE, et al. Early versus delayed invasive intervention in acute coronary syndromes N Engl J Med, 2009.PMID 19458363
  7. [7]Thiele H, Zeymer U, Neumann FJ, et al. Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial Lancet, 2013.PMID 24011548
  8. [8]Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial Lancet, 1999.PMID 10475182
  9. [9]Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction N Engl J Med, 2013.PMID 23473396
  10. [10]Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction N Engl J Med, 2017.PMID 28844200
  11. [11]Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med, 2006.PMID 16537663
  12. [12]Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA, 2004.PMID 15238590
  13. [13]Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med, 2007.PMID 17982182
  14. [14]Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med, 2003.PMID 12668699
  15. [15]Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med, 2004.PMID 15007110
  16. [16]Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction N Engl J Med, 2003.PMID 12930925
  17. [17]Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet, 1993.PMID 8104270
  18. [18]Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Circulation, 2025.PMID 40014670
  19. [19]Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J, 2018.PMID 28886621
  20. [20]Reimer KA, Lowe JE, Rasmussen MM, et al. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs Circulation, 1977.PMID 912839
  21. [21]Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making JAMA, 2000.PMID 10938172
  22. [22]Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department Int J Cardiol, 2013.PMID 23465250
  23. [23]Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data Lancet, 2008.PMID 18440425
  24. [24]Sgarbossa EB, Pinski SL, Barbagelata A, et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators N Engl J Med, 1996.PMID 8559200
  25. [25]DeGeare VS, Boura JA, Grines LL, et al. Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction Am J Cardiol, 2001.PMID 11348598
  26. [26]India State-Level Disease Burden Initiative CVD Collaborators The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016 Lancet Glob Health, 2018.PMID 30219317
  27. [27]Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies Lancet, 2010.PMID 20609967
  28. [28]Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction N Engl J Med, 2019.PMID 31475795
  29. [29]Meza-González YA, Manzur-Barbur MC, Ochoa-Díaz AF, et al. Untangling Mechanical Complications of Acute Myocardial Infarction JACC Case Rep, 2025.PMID 40185591
Acute Coronary Syndrome · NeetVellum